Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
5 High-Performing Cathie Wood Stocks as of June
06:06pm, Tuesday, 28'th Jun 2022
As investors continue grappling with a volatile stock market, five stocks in Catherine Wood (Trades, Portfolio)'s first-quarter 13F equity portfolio that have high GF Scores and have outperformed the
3 Cheap Growth Stocks Near Their 52-Week Lows to Buy and Forget
07:45am, Sunday, 26'th Jun 2022
Sometimes, the smart-money move is to dive in on a dip and leave your stocks alone for a decade or more.
Incyte: Growth Drivers Are Coming
03:01am, Friday, 17'th Jun 2022
Incyte's 1Q 2022 results look solid. Jakafi keeps good revenue growth. Lower gross/net discount in 2H could boost Opzelura net revenue growth.
Market Punishes Incyte After Company Eliminates Its Debt
11:04am, Wednesday, 08'th Jun 2022
Two developments could put Incyte Corporation ( INCY , Financial) into the realm of value stocks, in my opinion. First, it eliminated its long-term debt in 2018 (it had carried little or no short-term
CHMP Backs Approval of Lilly/Incyte's Olumiant For Patchy Hair Loss
03:08pm, Friday, 20'th May 2022
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Eli Lilly And Co (NYSE: LLY) and Incyte Corporation's (NASDAQ: INCY)
FDA approves Eli Lilly and Incyte's Olumiant for treatment of certain hospitalized adults with COVID-19
07:04am, Wednesday, 11'th May 2022
Eli Lilly & Co. LLY, -1.22% and Incyte INCY, +4.80% said Wednesday the Food and Drug Administration has approved the use of their Olumiant for the treatment of certain adults who are hospitalized with
Despite Q1 Earnings Miss, Incyte Shares Jump On Revised FY22 Sales Guidance
02:21pm, Tuesday, 03'rd May 2022
Incyte Corporation's (NASDAQ: INCY) Q1 adjusted EPS reached $0.55, compared to $0.67 posted a year ago. Analysts had estimated $0.68.
Incyte's (INCY) Q1 Earnings and Revenues Fall Shy of Estimates
01:33pm, Tuesday, 03'rd May 2022
Incyte's (INCY) earnings and revenues miss estimates in the first quarter of 2022. The company raises the bottom end of full-year Jakafi net product revenue guidance.
Incyte's (INCY) CEO Hervé Hoppenot on Q1 2022 Results - Earnings Call Transcript
11:29am, Tuesday, 03'rd May 2022
Incyte Corporation (NASDAQ:INCY ) Q1 2022 Earnings Conference Call May 3, 2022 8:00 AM ET Company Participants Christine Chiou – Head-Investor Relations Hervé Hoppenot – Chairman, President and C
Incyte (INCY) Lags Q1 Earnings and Revenue Estimates
09:47am, Tuesday, 03'rd May 2022
Incyte (INCY) delivered earnings and revenue surprises of -3.51% and 4%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks Q1 Earnings Due on May 3: PFE, BIIB & More
05:18pm, Monday, 02'nd May 2022
Let's look at the five biotech/pharma companies, slated to release quarterly results on May 3.
3 Top Biotech Stocks To Watch In May 2022
02:30pm, Monday, 02'nd May 2022
Which biotech stocks do you have on your May 2022 watchlist?
3 Nasdaq Stocks to Buy Now for Growth
06:15am, Sunday, 01'st May 2022
These are the best Nasdaq stocks to invest in now. INCY, ROKU and FTXL can make great investments in the rest of the year.
Incyte Is A Buy As Ruxolitinib Ramps Revenue And Pipeline Matures
06:14am, Thursday, 14'th Apr 2022
Jakafi (ruxolitinib) sales were up 15% y/y and the label is expanding. Olumiant is ramping up royalties.
Incyte to Report First Quarter Financial Results
08:00am, Tuesday, 12'th Apr 2022
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, May 3, 2022.
